Abstract
To report health-related quality of life (HRQOL) and toxicity outcomes at 4-year follow-up in prostate cancer patients treated with high-dose rate (HDR) brachytherapy as monotherapy using single-fraction of 19 Gy or 2 fractions of 13.5 Gy (27 Gy/2 fractions one week apart).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
